Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.09 | 7.66 | 3.21 | 6.29 | 5.64 | 5.40 | 5.22 | 4.83 | 5.16 | 3.85 | 5.47 | 7.57 |
| Expenses | 7.37 | 6.87 | 3.19 | 5.30 | 5.08 | 4.81 | 4.72 | 4.28 | 4.43 | 4.05 | 4.13 | 6.92 |
| Operating Profit | 0.72 | 0.79 | 0.02 | 0.99 | 0.56 | 0.59 | 0.50 | 0.55 | 0.73 | -0.20 | 1.34 | 0.65 |
| OPM % | 8.90% | 10.31% | 0.62% | 15.74% | 9.93% | 10.93% | 9.58% | 11.39% | 14.15% | -5.19% | 24.50% | 8.59% |
| Other Income | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Interest | 0.10 | 0.11 | 0.13 | 0.21 | 0.12 | 0.12 | 0.08 | 0.10 | 0.08 | 0.09 | 0.07 | 0.06 |
| Depreciation | 0.29 | 0.31 | 0.32 | 0.28 | 0.33 | 0.31 | 0.32 | 0.38 | 0.39 | 0.32 | 0.40 | 0.32 |
| Profit before tax | 0.33 | 0.37 | -0.43 | 0.50 | 0.11 | 0.16 | 0.10 | 0.07 | 0.26 | -0.61 | 0.87 | 0.27 |
| Tax % | 18.18% | 16.22% | -16.28% | 26.00% | 90.91% | 62.50% | -50.00% | 71.43% | 96.15% | -72.13% | 34.48% | 18.52% |
| Net Profit | 0.27 | 0.31 | -0.35 | 0.37 | 0.01 | 0.05 | 0.15 | 0.02 | 0.01 | -0.17 | 0.56 | 0.22 |
| EPS in Rs | 0.53 | 0.61 | -0.69 | 0.73 | 0.02 | 0.10 | 0.30 | 0.04 | 0.02 | -0.34 | 1.10 | 0.43 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.99 | 10.90 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 18.81 | 22.05 |
| Expenses | 12.49 | 10.96 | 14.04 | 11.78 | 11.87 | 12.58 | 14.04 | 24.84 | 24.45 | 19.91 | 16.87 | 19.53 |
| Operating Profit | 0.50 | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2.00 | 2.28 | 1.24 | 1.94 | 2.52 |
| OPM % | 3.85% | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 10.31% | 11.43% |
| Other Income | 0.37 | 0.27 | 0.69 | 0.24 | 0.23 | 0.64 | 0.16 | 0.27 | 0.40 | 1.41 | 0.49 | 0.00 |
| Interest | 0.21 | 0.20 | 0.13 | 0.15 | 0.32 | 0.47 | 0.46 | 0.47 | 0.47 | 0.54 | 0.35 | 0.30 |
| Depreciation | 0.41 | 0.38 | 0.33 | 0.32 | 0.66 | 1.27 | 1.09 | 0.81 | 1.20 | 1.26 | 1.49 | 1.43 |
| Profit before tax | 0.25 | -0.37 | 1.27 | 0.80 | 0.16 | 0.35 | -0.95 | 0.99 | 1.01 | 0.85 | 0.59 | 0.79 |
| Tax % | 32.00% | 18.92% | 22.05% | 26.25% | 68.75% | 31.43% | -30.53% | 22.22% | 23.76% | 34.12% | 27.12% | |
| Net Profit | 0.17 | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.57 | 0.42 | 0.62 |
| EPS in Rs | 0.34 | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.12 | 0.83 | 1.21 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 4% | 6% | -11% | 5% | ||
| Compounded Profit Growth | 9% | 44% | -18% | 170% | ||
| Stock Price CAGR | 3% | 9% | 4% | 8% | ||
| Return on Equity | 3% | 4% | 6% | 4% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 1.40 | 1.57 | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.39 | 4.79 |
| Borrowings | 1.72 | 1.69 | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.12 | 2.44 |
| Other Liabilities | 2.71 | 1.80 | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.38 | 2.65 |
| Total Liabilities | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.98 | 14.97 |
| Fixed Assets | 2.43 | 2.44 | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.24 | 7.04 |
| CWIP | 0.24 | -0.00 | -0.00 | 0.08 | 6.24 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.68 | 0.68 | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | -0.00 | -0.00 | -0.00 |
| Other Assets | 7.57 | 7.03 | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.74 | 7.93 |
| Total Assets | 10.92 | 10.15 | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.98 | 14.97 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0.70 | -0.13 | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.29 | 2.48 | 0.82 | 3.29 | 3.65 |
| Cash from Investing Activity | 0.02 | 0.17 | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.54 | -1.30 | -1.08 | -1.05 | -2.16 |
| Cash from Financing Activity | -0.09 | -0.23 | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.43 | -1.17 | 0.10 | -1.56 | -2.03 |
| Net Cash Flow | 0.63 | -0.19 | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 | -0.16 | 0.69 | -0.54 |
| Free Cash Flow | 0.47 | -0.33 | 0.19 | -0.01 | -2.87 | -1.70 | 0.10 | 0.10 | 1.73 | -0.51 | 1.10 | -0.17 |
| CFO/OP | 125% | 6% | -833% | 1% | 350% | 36% | 25% | -43% | 127% | 45% | 280% | 196% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 102.08 | 100.59 | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 | 40.56 |
| Inventory Days | 64.34 | 65.28 | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | 245.67 | ||||
| Days Payable | 69.91 | 34.34 | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | 758.08 | ||||
| Cash Conversion Cycle | 96.50 | 131.54 | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 | 40.56 |
| Working Capital Days | 38.35 | 58.44 | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 47.14 | 46.51 | 57.90 | 68.00 | 40.36 |
| ROCE % | 5.20% | 5.56% | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.07% | 7.25% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 27.48% | 27.82% |
| Public | 73.62% | 73.62% | 73.61% | 73.61% | 73.62% | 73.62% | 73.61% | 73.61% | 73.62% | 73.62% | 72.53% | 72.19% |
| No. of Shareholders | 6,805 | 6,852 | 7,257 | 7,325 | 7,364 | 7,429 | 7,431 | 7,415 | 7,446 | 7,409 | 7,349 | 7,309 |
Fundamentals
Market Cap₹ 12.7 Cr.
Current Price₹ 25.0
Stock P/E20.4
Book Value₹ 19.5
ROCE7.25 %
ROE4.34 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)5%
Compounded Profit Growth (TTM)170%
Standalone figures.
Valuation
Market capRs 13 Cr
Enterprise valueRs 15 Cr
P/E (TTM)20.78x
Price to book1.30x
Price to sales0.58x
EV / EBITDA5.97x
EV / EBIT13.81x
EV / sales0.68x
Price to cash flow3.53x
Earnings yield4.81%
P/E, 3-year average20.58x
P/B, 3-year average1.27x
P/E, 5-year average17.46x
P/B, 5-year average1.06x
Profitability
Operating margin (excl. other income)10.31%
Operating margin (incl. other income)12.92%
EBITDA margin11.43%
Pre-tax margin3.58%
Net profit margin2.81%
Net margin, latest quarter2.91%
ROE4.34%
ROCE7.25%
ROA2.71%
ROE, 3-year average6.53%
ROCE, 3-year average9.48%
ROA, 3-year average3.51%
ROE, 5-year average4.19%
ROCE, 5-year average7.24%
ROA, 5-year average2.25%
ROIC (approx.)6.59%
Tax rate27.12%
Other income / net worth4.96%
Growth
Sales growth (latest year)-11.06%
Profit growth (latest year)-26.32%
Sales CAGR, 3 years-11.18%
Sales CAGR, 5 years6.04%
Profit CAGR, 3 years-18.29%
Profit CAGR, 5 years11.84%
Sales growth QoQ38.39%
Profit growth QoQ-60.71%
Sales growth YoY (latest quarter)56.73%
Profit growth YoY (latest quarter)1000.00%
Per share
EPS (TTM)Rs 1.22
EPS (latest year)Rs 0.82
EPS (latest quarter)Rs 0.43
EPS, 3-year averageRs 1.15
EPS, 5-year averageRs 0.73
Book value per shareRs 19.40
Sales per shareRs 43.29
Cash flow per shareRs 7.17
Free cash flow per shareRs -0.33
Efficiency
Asset turnover1.26x
Fixed asset turnover2.67x
Inventory turnover4.30x
Inventory days85 days
Debtor days41 days
Debtors turnover9.00x
Creditor days758 days
Cash conversion cycle41 days
Working capital days40 days
Leverage
Total debtRs 2 Cr
Cash and bankRs 0 Cr
Net debtRs 2 Cr
Debt to equity0.25x
Net debt / EBITDA0.86x
Interest coverage3.63x
Owners' fund to total sources66.00%
Debt to assets16.30%
Cash flow
Cash from Operating Activity (latest year)Rs 4 Cr
Cash from Investing Activity (latest year)Rs -2 Cr
Cash from Financing Activity (latest year)Rs -2 Cr
Net Cash Flow (latest year)Rs -1 Cr
Free cash flow (latest year)Rs -0 Cr
FCFE (approx.: FCF + change in debt)Rs -2 Cr
Cash from ops / profit, 5 years5.32x
Sales to cash flow5.15x
Statement figures
Net sales (TTM)Rs 22 Cr
Net sales (latest year)Rs 19 Cr
Sales (latest quarter)Rs 8 Cr
Operating profit excl. other income (latest year)Rs 2 Cr
Operating profit (latest quarter)Rs 1 Cr
Other income (TTM)Rs 0 Cr
EBITDA (TTM)Rs 3 Cr
PBDT (TTM)Rs 2 Cr
Profit before tax (TTM)Rs 1 Cr
Tax (latest year)Rs 0 Cr
Net profit (TTM)Rs 1 Cr
Net profit (latest year)Rs 0 Cr
Net profit (latest quarter)Rs 0 Cr
Depreciation (TTM)Rs 1 Cr
Depreciation (latest quarter)Rs 0 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 13 Cr
Total expenditure (latest year)Rs 17 Cr
Total income (latest year)Rs 19 Cr
Share capitalRs 5 Cr
ReservesRs 5 Cr
Shareholders' fundsRs 10 Cr
Total assetsRs 15 Cr
Net blockRs 7 Cr
ReceivablesRs 2 Cr
InventoryRs 3 Cr
Other liabilitiesRs 3 Cr
Shares outstanding (crore)0.51
Ownership
Promoter holding27.82% (+1.44 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/E 20.8 is at the 50th percentile of its own 7.2-year range
(median 20.7, low 3.0, high 155.7).
P/B 1.30 is at the 81th percentile (median 0.94).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | 524606 | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +5.6% | -2.8% | +8.3 pts |
| 1 month | +13.6% | -6.8% | +20.4 pts |
| 3 months | +14.7% | -7.6% | +22.3 pts |
| 3 years | +17.4% | +14.2% | +3.2 pts |
| 5 years | +51.9% | +27.9% | +24.0 pts |
Red flags
F-score 6 of 8| look | Inventory outrunning sales Inventory grew 65% vs sales -11% in 2026 |
| look | Profit leans on other income Other income was 83% of pre-tax profit in 2026 |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹8 Cr +56.7% vs Jun 2025.
Net profit ₹0 Cr +1000.0%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Beryl Drugs Ltd?
Beryl Drugs Ltd (524606) has a market capitalisation of Rs 12.7 Cr. at the 2026-10-01 close.
What is the P/E ratio of Beryl Drugs Ltd?
Beryl Drugs Ltd trades at a P/E of 20.4 on trailing twelve-month profit, at the 2026-10-01 close.
What were Beryl Drugs Ltd's latest quarterly results?
In the Jun 2026 quarter, Beryl Drugs Ltd sales was Rs 8 Cr (+56.7% vs Jun 2025) and net profit was Rs 0 Cr.